{
    "markdown": "<a id='2dc95742-a42a-4361-a793-2e5ceb7a2bf5'></a>\n\nBaron\n\n<a id='da8abeee-6667-4fa6-9c90-c8f37a75c31c'></a>\n\n8.\n\n<a id='04f1bb98-2597-49ce-860b-de3e26faa844'></a>\n\n12-4-13 pv\n\n<a id='8ec3daf4-4fd9-46ca-934e-09e4a0c54e78'></a>\n\ndraft\n\n<a id='be168755-f81f-413c-ad8a-fc650c9ef34a'></a>\n\nFDA Conference Call: August 13, 2002\n\n<a id='c947c7f1-b515-43b1-82b0-14d6880a5969'></a>\n\nFDA Personnel:\nJeri El-Hage, Ph.D., Toxicology Team Leader\nJena Weber, Project Manager\n\n<a id='2d3f5a74-fe5b-4acb-a748-6afea768db66'></a>\n\n**TPNA Personnel:**\n\nDavid Baron, Ph.D., Director, Nonclinical Safety and Efficacy\nJanet Haskins, Manager, Regulatory Affairs\nPat Frank, Ph.D., TPNA Consultant\n\n<a id='4f002efa-c39b-47ed-b0aa-fc6e2710c281'></a>\n\nThis teleconference was held as a follow-up to a discussion between TPNA and the\nAgency on July 31, 2002. The purpose of this conference call was so that Dr. El-\nHage could expand upon the nonclinical data related to dual PPAR agonist that was\ndiscussed shared-with TPNA onduring-the July 31, 2002 conference call.\n\n<a id='add73907-9cd6-4f87-b12e-77c5c62428a8'></a>\n\nDr. El-Hage informed TPNA that nonclinical data observed in several standard 2-year rat and mouse bioassay studies with several other dual PPAR agonists, similar to pioglitazone, were shown to cause transitional cell tumors in the bladder and kidneys of male and female rats and male mice. Therefore, the Division is considering the relevance of these findings to becoming concerned with the potentially long term tumorigenic effects of this class of drugs, in humans. She also noted that in follow-up unspecified mechanistic studies, no evidence of irritation by crystalluria or calculi was noted.\n\n<a id='d6e2a69c-50cb-48af-a5ab-1ee030091343'></a>\n\nDr. El-Hage then described a tumor promoter-model study that was conducted by another sponsorcompany in which pioglitazone was administered. The study was designed as follows:\n\n* BBN was given to male Fisher rats in their drinking water for four weeks.\n* Four groups were designated:\n  * Pioglitazone 40 mg/kg/day after BBN\n\n<a id='ace7c294-880b-4eac-be4a-019dfc2a9ebf'></a>\n\nConfidential - Subject to Protective Order\n\n<a id='338f2a1f-db86-4fb7-9b10-10b34e455d74'></a>\n\nTAK-BAROND-00301714\nProduced in MDL on 09/08/12\n\n<a id='eada67b0-eb53-4172-8735-d9af590c2555'></a>\n\nSource: https://www.indupP6319-00001ts.ucsf.edu/docs/rtjf0226",
    "chunks": [
        {
            "markdown": "<a id='2dc95742-a42a-4361-a793-2e5ceb7a2bf5'></a>\n\nBaron",
            "type": "marginalia",
            "id": "2dc95742-a42a-4361-a793-2e5ceb7a2bf5",
            "grounding": {
                "box": {
                    "left": 0.6576353311538696,
                    "top": 0.03727763146162033,
                    "right": 0.7811540365219116,
                    "bottom": 0.07602272927761078
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='da8abeee-6667-4fa6-9c90-c8f37a75c31c'></a>\n\n8.",
            "type": "marginalia",
            "id": "da8abeee-6667-4fa6-9c90-c8f37a75c31c",
            "grounding": {
                "box": {
                    "left": 0.892540454864502,
                    "top": 0.03532865643501282,
                    "right": 0.938139796257019,
                    "bottom": 0.06987488269805908
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='04f1bb98-2597-49ce-860b-de3e26faa844'></a>\n\n12-4-13 pv",
            "type": "marginalia",
            "id": "04f1bb98-2597-49ce-860b-de3e26faa844",
            "grounding": {
                "box": {
                    "left": 0.8046662211418152,
                    "top": 0.07088764011859894,
                    "right": 0.9429990649223328,
                    "bottom": 0.09385977685451508
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='8ec3daf4-4fd9-46ca-934e-09e4a0c54e78'></a>\n\ndraft",
            "type": "text",
            "id": "8ec3daf4-4fd9-46ca-934e-09e4a0c54e78",
            "grounding": {
                "box": {
                    "left": 0.4674726128578186,
                    "top": 0.07659273594617844,
                    "right": 0.526155948638916,
                    "bottom": 0.10298135131597519
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='be168755-f81f-413c-ad8a-fc650c9ef34a'></a>\n\nFDA Conference Call: August 13, 2002",
            "type": "text",
            "id": "be168755-f81f-413c-ad8a-fc650c9ef34a",
            "grounding": {
                "box": {
                    "left": 0.1619223803281784,
                    "top": 0.11579874157905579,
                    "right": 0.48223745822906494,
                    "bottom": 0.13966262340545654
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='c947c7f1-b515-43b1-82b0-14d6880a5969'></a>\n\nFDA Personnel:\nJeri El-Hage, Ph.D., Toxicology Team Leader\nJena Weber, Project Manager",
            "type": "text",
            "id": "c947c7f1-b515-43b1-82b0-14d6880a5969",
            "grounding": {
                "box": {
                    "left": 0.16180013120174408,
                    "top": 0.14911699295043945,
                    "right": 0.5101081728935242,
                    "bottom": 0.2192142903804779
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='2d3f5a74-fe5b-4acb-a748-6afea768db66'></a>\n\n**TPNA Personnel:**\n\nDavid Baron, Ph.D., Director, Nonclinical Safety and Efficacy\nJanet Haskins, Manager, Regulatory Affairs\nPat Frank, Ph.D., TPNA Consultant",
            "type": "text",
            "id": "2d3f5a74-fe5b-4acb-a748-6afea768db66",
            "grounding": {
                "box": {
                    "left": 0.16135749220848083,
                    "top": 0.23689709603786469,
                    "right": 0.629204511642456,
                    "bottom": 0.3237205743789673
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='4f002efa-c39b-47ed-b0aa-fc6e2710c281'></a>\n\nThis teleconference was held as a follow-up to a discussion between TPNA and the\nAgency on July 31, 2002. The purpose of this conference call was so that Dr. El-\nHage could expand upon the nonclinical data related to dual PPAR agonist that was\ndiscussed shared-with TPNA onduring-the July 31, 2002 conference call.",
            "type": "text",
            "id": "4f002efa-c39b-47ed-b0aa-fc6e2710c281",
            "grounding": {
                "box": {
                    "left": 0.157842218875885,
                    "top": 0.3473972678184509,
                    "right": 0.8295739889144897,
                    "bottom": 0.4440586566925049
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='add73907-9cd6-4f87-b12e-77c5c62428a8'></a>\n\nDr. El-Hage informed TPNA that nonclinical data observed in several standard 2-year rat and mouse bioassay studies with several other dual PPAR agonists, similar to pioglitazone, were shown to cause transitional cell tumors in the bladder and kidneys of male and female rats and male mice. Therefore, the Division is considering the relevance of these findings to becoming concerned with the potentially long term tumorigenic effects of this class of drugs, in humans. She also noted that in follow-up unspecified mechanistic studies, no evidence of irritation by crystalluria or calculi was noted.",
            "type": "text",
            "id": "add73907-9cd6-4f87-b12e-77c5c62428a8",
            "grounding": {
                "box": {
                    "left": 0.15852975845336914,
                    "top": 0.46508121490478516,
                    "right": 0.8302488923072815,
                    "bottom": 0.6328657865524292
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='d6e2a69c-50cb-48af-a5ab-1ee030091343'></a>\n\nDr. El-Hage then described a tumor promoter-model study that was conducted by another sponsorcompany in which pioglitazone was administered. The study was designed as follows:\n\n* BBN was given to male Fisher rats in their drinking water for four weeks.\n* Four groups were designated:\n  * Pioglitazone 40 mg/kg/day after BBN",
            "type": "text",
            "id": "d6e2a69c-50cb-48af-a5ab-1ee030091343",
            "grounding": {
                "box": {
                    "left": 0.15888932347297668,
                    "top": 0.6535528302192688,
                    "right": 0.8293471336364746,
                    "bottom": 0.8002634644508362
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='ace7c294-880b-4eac-be4a-019dfc2a9ebf'></a>\n\nConfidential - Subject to Protective Order",
            "type": "marginalia",
            "id": "ace7c294-880b-4eac-be4a-019dfc2a9ebf",
            "grounding": {
                "box": {
                    "left": 0.05406571924686432,
                    "top": 0.9342165589332581,
                    "right": 0.32607561349868774,
                    "bottom": 0.9535725712776184
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='338f2a1f-db86-4fb7-9b10-10b34e455d74'></a>\n\nTAK-BAROND-00301714\nProduced in MDL on 09/08/12",
            "type": "marginalia",
            "id": "338f2a1f-db86-4fb7-9b10-10b34e455d74",
            "grounding": {
                "box": {
                    "left": 0.7304244041442871,
                    "top": 0.9339687824249268,
                    "right": 0.9308959245681763,
                    "bottom": 0.9651542901992798
                },
                "page": 0
            }
        },
        {
            "markdown": "<a id='eada67b0-eb53-4172-8735-d9af590c2555'></a>\n\nSource: https://www.indupP6319-00001ts.ucsf.edu/docs/rtjf0226",
            "type": "marginalia",
            "id": "eada67b0-eb53-4172-8735-d9af590c2555",
            "grounding": {
                "box": {
                    "left": 0.22434240579605103,
                    "top": 0.9778140187263489,
                    "right": 0.7778109908103943,
                    "bottom": 0.9999250769615173
                },
                "page": 0
            }
        }
    ],
    "splits": [
        {
            "class": "full",
            "identifier": "full",
            "pages": [
                0
            ],
            "markdown": "<a id='2dc95742-a42a-4361-a793-2e5ceb7a2bf5'></a>\n\nBaron\n\n<a id='da8abeee-6667-4fa6-9c90-c8f37a75c31c'></a>\n\n8.\n\n<a id='04f1bb98-2597-49ce-860b-de3e26faa844'></a>\n\n12-4-13 pv\n\n<a id='8ec3daf4-4fd9-46ca-934e-09e4a0c54e78'></a>\n\ndraft\n\n<a id='be168755-f81f-413c-ad8a-fc650c9ef34a'></a>\n\nFDA Conference Call: August 13, 2002\n\n<a id='c947c7f1-b515-43b1-82b0-14d6880a5969'></a>\n\nFDA Personnel:\nJeri El-Hage, Ph.D., Toxicology Team Leader\nJena Weber, Project Manager\n\n<a id='2d3f5a74-fe5b-4acb-a748-6afea768db66'></a>\n\n**TPNA Personnel:**\n\nDavid Baron, Ph.D., Director, Nonclinical Safety and Efficacy\nJanet Haskins, Manager, Regulatory Affairs\nPat Frank, Ph.D., TPNA Consultant\n\n<a id='4f002efa-c39b-47ed-b0aa-fc6e2710c281'></a>\n\nThis teleconference was held as a follow-up to a discussion between TPNA and the\nAgency on July 31, 2002. The purpose of this conference call was so that Dr. El-\nHage could expand upon the nonclinical data related to dual PPAR agonist that was\ndiscussed shared-with TPNA onduring-the July 31, 2002 conference call.\n\n<a id='add73907-9cd6-4f87-b12e-77c5c62428a8'></a>\n\nDr. El-Hage informed TPNA that nonclinical data observed in several standard 2-year rat and mouse bioassay studies with several other dual PPAR agonists, similar to pioglitazone, were shown to cause transitional cell tumors in the bladder and kidneys of male and female rats and male mice. Therefore, the Division is considering the relevance of these findings to becoming concerned with the potentially long term tumorigenic effects of this class of drugs, in humans. She also noted that in follow-up unspecified mechanistic studies, no evidence of irritation by crystalluria or calculi was noted.\n\n<a id='d6e2a69c-50cb-48af-a5ab-1ee030091343'></a>\n\nDr. El-Hage then described a tumor promoter-model study that was conducted by another sponsorcompany in which pioglitazone was administered. The study was designed as follows:\n\n* BBN was given to male Fisher rats in their drinking water for four weeks.\n* Four groups were designated:\n  * Pioglitazone 40 mg/kg/day after BBN\n\n<a id='ace7c294-880b-4eac-be4a-019dfc2a9ebf'></a>\n\nConfidential - Subject to Protective Order\n\n<a id='338f2a1f-db86-4fb7-9b10-10b34e455d74'></a>\n\nTAK-BAROND-00301714\nProduced in MDL on 09/08/12\n\n<a id='eada67b0-eb53-4172-8735-d9af590c2555'></a>\n\nSource: https://www.indupP6319-00001ts.ucsf.edu/docs/rtjf0226",
            "chunks": [
                "2dc95742-a42a-4361-a793-2e5ceb7a2bf5",
                "da8abeee-6667-4fa6-9c90-c8f37a75c31c",
                "04f1bb98-2597-49ce-860b-de3e26faa844",
                "8ec3daf4-4fd9-46ca-934e-09e4a0c54e78",
                "be168755-f81f-413c-ad8a-fc650c9ef34a",
                "c947c7f1-b515-43b1-82b0-14d6880a5969",
                "2d3f5a74-fe5b-4acb-a748-6afea768db66",
                "4f002efa-c39b-47ed-b0aa-fc6e2710c281",
                "add73907-9cd6-4f87-b12e-77c5c62428a8",
                "d6e2a69c-50cb-48af-a5ab-1ee030091343",
                "ace7c294-880b-4eac-be4a-019dfc2a9ebf",
                "338f2a1f-db86-4fb7-9b10-10b34e455d74",
                "eada67b0-eb53-4172-8735-d9af590c2555"
            ]
        }
    ],
    "grounding": {
        "2dc95742-a42a-4361-a793-2e5ceb7a2bf5": {
            "box": {
                "left": 0.6576353311538696,
                "top": 0.03727763146162033,
                "right": 0.7811540365219116,
                "bottom": 0.07602272927761078
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "da8abeee-6667-4fa6-9c90-c8f37a75c31c": {
            "box": {
                "left": 0.892540454864502,
                "top": 0.03532865643501282,
                "right": 0.938139796257019,
                "bottom": 0.06987488269805908
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "04f1bb98-2597-49ce-860b-de3e26faa844": {
            "box": {
                "left": 0.8046662211418152,
                "top": 0.07088764011859894,
                "right": 0.9429990649223328,
                "bottom": 0.09385977685451508
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "8ec3daf4-4fd9-46ca-934e-09e4a0c54e78": {
            "box": {
                "left": 0.4674726128578186,
                "top": 0.07659273594617844,
                "right": 0.526155948638916,
                "bottom": 0.10298135131597519
            },
            "page": 0,
            "type": "chunkText"
        },
        "be168755-f81f-413c-ad8a-fc650c9ef34a": {
            "box": {
                "left": 0.1619223803281784,
                "top": 0.11579874157905579,
                "right": 0.48223745822906494,
                "bottom": 0.13966262340545654
            },
            "page": 0,
            "type": "chunkText"
        },
        "c947c7f1-b515-43b1-82b0-14d6880a5969": {
            "box": {
                "left": 0.16180013120174408,
                "top": 0.14911699295043945,
                "right": 0.5101081728935242,
                "bottom": 0.2192142903804779
            },
            "page": 0,
            "type": "chunkText"
        },
        "2d3f5a74-fe5b-4acb-a748-6afea768db66": {
            "box": {
                "left": 0.16135749220848083,
                "top": 0.23689709603786469,
                "right": 0.629204511642456,
                "bottom": 0.3237205743789673
            },
            "page": 0,
            "type": "chunkText"
        },
        "4f002efa-c39b-47ed-b0aa-fc6e2710c281": {
            "box": {
                "left": 0.157842218875885,
                "top": 0.3473972678184509,
                "right": 0.8295739889144897,
                "bottom": 0.4440586566925049
            },
            "page": 0,
            "type": "chunkText"
        },
        "add73907-9cd6-4f87-b12e-77c5c62428a8": {
            "box": {
                "left": 0.15852975845336914,
                "top": 0.46508121490478516,
                "right": 0.8302488923072815,
                "bottom": 0.6328657865524292
            },
            "page": 0,
            "type": "chunkText"
        },
        "d6e2a69c-50cb-48af-a5ab-1ee030091343": {
            "box": {
                "left": 0.15888932347297668,
                "top": 0.6535528302192688,
                "right": 0.8293471336364746,
                "bottom": 0.8002634644508362
            },
            "page": 0,
            "type": "chunkText"
        },
        "ace7c294-880b-4eac-be4a-019dfc2a9ebf": {
            "box": {
                "left": 0.05406571924686432,
                "top": 0.9342165589332581,
                "right": 0.32607561349868774,
                "bottom": 0.9535725712776184
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "338f2a1f-db86-4fb7-9b10-10b34e455d74": {
            "box": {
                "left": 0.7304244041442871,
                "top": 0.9339687824249268,
                "right": 0.9308959245681763,
                "bottom": 0.9651542901992798
            },
            "page": 0,
            "type": "chunkMarginalia"
        },
        "eada67b0-eb53-4172-8735-d9af590c2555": {
            "box": {
                "left": 0.22434240579605103,
                "top": 0.9778140187263489,
                "right": 0.7778109908103943,
                "bottom": 0.9999250769615173
            },
            "page": 0,
            "type": "chunkMarginalia"
        }
    },
    "metadata": {
        "filename": "rtjf0226_1.png",
        "org_id": null,
        "page_count": 1,
        "duration_ms": 7213,
        "credit_usage": 3.0,
        "job_id": "p8vtvfxbhksc7dsx5yxwm1n9p",
        "version": "dpt-2-20250919"
    }
}